Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MBTD1 | Q05BQ5 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8442929 | 1.00 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL8442460 | 1.00 | L3MBTL3 (0.51) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL23269642 | 0.97 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| Hydrochloric Acid SCHEMBL6601123 | 0.97 | ALDH1A1 (0.53) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| Hydrochloric Acid SCHEMBL23123299 | 0.97 | ALDH1A1 (0.53) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL107233 | 0.97 | L3MBTL3 (0.53) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL25855899 | 0.93 | L3MBTL3 (0.47) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL17695417 | 0.93 | ALDH1A1 (0.50) | L3MBTL3L3MBTL1ALDH1A1MBTD1CYP2D6 | |
| SCHEMBL4400116 | 0.92 | ALDH1A1 (0.52) | L3MBTL3L3MBTL1ALDH1A1MBTD1KDM4E | |
| SCHEMBL13330131 | 0.91 | L3MBTL3 (0.50) | L3MBTL3L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 906 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3626717-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2020-03-25 | — | — | EP | claimed |
| US-RE47193-E1 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-01-08 | — | — | US | claimed |
| US-9428495-B2 | Selectively substituted quinoline compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-30 | — | — | US | claimed |
| EP-3057964-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | Eisai R&D Management Co., Ltd. (JP) | 2016-08-24 | — | — | EP | claimed |
| WO-2015057659-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-23 | — | — | WO | claimed |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-16 | — | — | US | claimed |
| US-7745641-B2 | Nitrogen-containing heterocyclic compound | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2010-06-29 | — | — | US | claimed |
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | claimed |
| US-20090054460-A1 | Piperazine derivatives and methods of use | CHEN JIAN J | 2009-02-26 | — | — | US | claimed |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | AMGEN, INC. (US) | 2009-02-19 | — | — | US | claimed |
| WO-2006044412-A1 | NOVEL B1 BRADYKININ RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006044355-A1 | TRIAZOLES AND THEIR USE AS BRADYKININ B1 RECEPTOR ANTAGONISTS | AMGEN INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2006041888-A2 | SUBSTITUTED ARYL OR HETEROARYLSULFONYLBUTANAMIDES FOR USE AS ANTI-INFLAMMATORY AGENTS | AMGEN INC. (US) | 2006-04-20 | — | — | WO | claimed |
| EP-1631542-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | Amgen, Inc. (US) | 2006-03-08 | — | — | EP | claimed |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | AMGEN INC. | 2005-10-20 | — | — | US | claimed |
| WO-2005061467-A2 | PIPERAZINE DERIVATIVES AS BRADYKININ ANTAGONISTS | AMGEN INC. (US) | 2005-07-07 | — | — | WO | claimed |
| US-20050124654-A1 | Compounds and methods of use | AMGEN INC. | 2005-06-09 | — | — | US | claimed |
| WO-2005049604-A2 | ANTITHROMBOTIC AROMATIC ETHERS | ELI LILLY AND COMPANY (US) | 2005-06-02 | — | — | WO | claimed |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | AMGEN INC. | 2005-01-20 | — | — | US | claimed |
| WO-2004092116-A1 | BICYCLIC COMPOUNDS HAVING BRADYKININ RECEPTORS AFFINITY AND PHARMACEUTICAL COMPOSITIONS THEREOF | AMGEN, INC. (US) | 2004-10-28 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124654-A1 | Compounds and methods of use | LTC4S, PTGES, LTB4R2 | L3MBTL3 2540/4885L3MBTL1 2757/4885ALDH1A1 353/4885 |
| US-20090048224-A1 | COMPOUNDS AND METHODS OF USE | LTC4S, PTGES, LTB4R2 | L3MBTL3 2540/4885L3MBTL1 2757/4885ALDH1A1 353/4885 |
| US-20090054460-A1 | Piperazine derivatives and methods of use | PTGES, PTGES2, PTGIS | L3MBTL3 3636/4885L3MBTL1 3856/4885ALDH1A1 184/4885 |
| US-20150105370-A1 | SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS | SSB, TLR7, TLR8 | L3MBTL3 2773/4885L3MBTL1 2863/4885ALDH1A1 4592/4885 |
| US-20050234044-A1 | Cyclic amine derivatives and methods of use | PTGIS, BDKRB2, LTC4S | L3MBTL3 2629/4885L3MBTL1 3111/4885ALDH1A1 616/4885 |
| US-20050014749-A1 | analgesics; antiinflammatory agents; antiarthritic agents;Alzheimer's disease; cirrhosis; antiallergens; antihistamines ; anticancer agents; vision defects | ACHE, TNF, BCHE | L3MBTL3 2661/4885L3MBTL1 2725/4885ALDH1A1 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.